Mathematical models of targeted cancer therapy

被引：38

作者：

Abbott, L. H.

Michor, F. ^{[1
]}

机构：

[1] Harvard Univ, Soc Fellows, Cambridge, MA 02138 USA

[2] Harvard Univ, Program Evolutionary Dynam, Cambridge, MA 02138 USA

来源：

BRITISH JOURNAL OF CANCER | 2006年 / 95卷 / 09期

关键词：

targeted cancer therapy; mathematical biology; chronic myeloid leukaemia;

D O I：

10.1038/sj.bjc.6603310

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Improved understanding of the molecular underpinnings of cancer initiation and progression has led to the development of targeted cancer therapies. The importance of these new methods of cancer treatment necessitates further research into the dynamic interactions between cancer cells and therapeutic agents, as well as a means of analysing their relationship quantitatively. The present review outlines the application of mathematical modelling to the dynamics of targeted cancer therapy, focusing particular attention on chronic myeloid leukaemia and its treatment with imatinib (Glivec).

引用

收藏

页码：1136 / 1141

页数：6

相关论文

共 38 条

[21] Two genetic hits (more or less) to cancer [J].

Knudson, AG .

NATURE REVIEWS CANCER, 2001, 1 (02) :157-162

[22] Drug resistance in cancer: Principles of emergence and prevention [J].

Komarova, NL ;

Wodarz, D .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (27) :9714-9719

[23] Cancer - Encouraging results for second-generation antiangiogenesis drugs [J].

Marx, J .

SCIENCE, 2005, 308 (5726) :1248-1249

[24] Dynamics of chronic myeloid leukaemia [J].

Michor, F ;

Hughes, TP ;

Iwasa, Y ;

Branford, S ;

Shah, NP ;

Sawyers, CL ;

Nowak, MA .

NATURE, 2005, 435 (7046) :1267-1270

[25] Evolution of resistance to cancer therapy [J].

Michor, F ;

Nowak, MA ;

Iwasa, Y .

CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (03) :261-271

[26] Dynamics of cancer progression [J].

Michor, F ;

Iwasa, Y ;

Nowak, MA .

NATURE REVIEWS CANCER, 2004, 4 (03) :197-205

[27] MUTATION AND CANCER - A MODEL FOR HUMAN CARCINOGENESIS [J].

MOOLGAVKAR, SH ;

KNUDSON, AG .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1981, 66 (06) :1037-1052

[28] Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C [J].

Müller, MC ;

Gattermann, N ;

Lahaye, T ;

Deininger, MWN ;

Berndt, A ;

Fruehauf, S ;

Neubauer, A ;

Fischer, T ;

Hossfeld, DK ;

Schneller, F ;

Krause, SW ;

Nerl, C ;

Sayer, HG ;

Ottmann, OG ;

Waller, C ;

Aulitzky, W ;

le Coutre, P ;

Freund, M ;

Merx, K ;

Paschka, P ;

König, H ;

Kreil, S ;

Berger, U ;

Gschaidmeier, H ;

Hehlmann, R ;

Hochhaus, A .

LEUKEMIA, 2003, 17 (12) :2392-2400

[29]

Nowak MA, 2000, VIRUS DYNAMICS

[30] Targeted cancer therapy [J].

Sawyers, C .

NATURE, 2004, 432 (7015) :294-297

← 1 2 3 4 →